Corgi Data & Surveillance ETF EYES

Corgi Data & Surveillance ETF es un activo que puedes comprar desde Chile con Racional. Conoce a qué se dedica, cómo se compone y qué lo mueve en el mercado, junto con sus datos clave para decidir si calza con tus metas de largo plazo.

• The Motley Fool 29 ago

  Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

  Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.

  

• GlobeNewswire Inc. 14 jul

  Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream

  EmergingGrowth.com announces the 94th Emerging Growth Conference scheduled for July 15-16, 2026, featuring presentations from 20+ small-cap and emerging growth companies across sectors including mining, technology, healthcare, and renewable energy. The virtual conference allows companies to present their strategies, products, and announcements to the investment community.

  

• GlobeNewswire Inc. 2 jul

  Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

  Vivani Medical announced a definitive merger agreement to merge its wholly owned subsidiary Cortigent, Inc. with ClearOne, Inc. Under the transaction, Cortigent will become a wholly owned subsidiary of ClearOne, which will be renamed Cortigent Holdings, Inc. and trade under ticker symbol 'CRGT'. ClearOne will raise $10-15 million in concurrent financing. Vivani will receive 12.5 million shares and own 59.4-67.5% of the combined company. The transaction is expected to close in Q3 2026.